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Summary 
The superantigen staphylococcal enterotoxin A (SEA) binds to major histocompatibility complex 
(MHC) class II molecules at two sites on either side of the peptide groove. Two separate but 
cooperative interactions to the human class II molecule HLA-DK1 were detected. The first high 
affinity interaction to the DR1 ~ chain is mediated by a zinc atom coordinated by H187, H225, 
and D227 in SEA and H81 in the polymorphic DR1/~ chain. The second low affinity site is 
to the DR1 ot chain analogous to SEB binding and is mediated by residue F47 in SEA. Binding 
of one SEA to the DR1/~ chain enhances the binding of a second SEA molecule to the DR1 
ot chain.  The zinc site is on the opposite  side of the SEA molecule from residue F47 so that 
one SEA molecule  can readily bind two class II molecules. Both binding sites on SEA are required 
for maximal activity. Thus, unlike SEB, SEA requires two separate binding sites for optimal 
activity, which may allow it to stabilize SEA interaction with T  cell receptors,  as well as to 
activate the antigen-presenting cell by cross-linking  MHC class II. 
S 
uperantigens  such  as  staphylococcal  enterotoxins  A-E 
(SEA-E)  1 bind to most MHC class II antigens (1-3) and 
stimulate virtually all T cells bearing particular V~ domains 
of  the c~/~ TCK without conventional MHC restriction (4-7). 
In a generally accepted model, superantigens simultaneously 
bind to MHC class II and the TCK by attaching to the side 
of both molecules (8-10,  11). While superantigens  such as 
SEA have an absolute dependence on presentation by MHC 
class II, polymorphisms in MHC and TCR as a rule do not 
generally affect superantigen recognition (5, 12-13), so it is 
uncertain what role the MHC class II molecule plays in su- 
perantigen activation. 
The staphylococcal enterotoxins  are small basic proteins 
responsible for food poisoning and toxic shock syndrome in 
humans. Most but not all of their toxic sequelae are attrib- 
uted to their ability to induce massive cytokine secretion (16), 
but it is still uncertain what benefit superantigens confer to 
the bacteria other than to induce general immunosuppres- 
sion that allows the bacteria to grow in the absence of a host 
immune response. 
The crystal structure of staphylococcal  enterotoxin B (SEB) 
has been resolved (17) along with a cocrystal of SEB bound 
to the human class II molecule HLA-DK1 (18). SEB binds 
to a conserved hydrophobic pocket in the or1 domain of the 
ot chain of HLA-DR1 via key SEB residues F44 and L45, 
1 Abbreviation used in this paper: SEA-E, staphylococcal enterotoxins  A-E. 
which together form an exposed hydrophobic ridge. In this 
position,  SEB residues identified as TCK contact residues 
(19-21), are positioned alongside the DKlot chain in a posi- 
tion to ligate the TCR Vfl loop (11). 
Considerable evidence from competition studies suggests 
that SEA and SEB do not bind in the same way to MHC 
class II molecules. For instance, SEA readily inhibits  SEB 
binding to MHC class II, but excess SEB does not prevent 
SEA binding (2, 21, 22). Furthermore, SEA (and SEE and 
SED) require a single zinc atom for high affinity binding to 
MHC class II, and a single metal binding site with a dissoci- 
ation constant of 2 #M has been located in SEA (23). In ad- 
dition, SEA requires residue H81 in the B chain a  helix on 
the opposite  side from the SEB binding site (24-26).  The 
observations that SEA and SEE both require zinc for MHC 
class II binding and that histidine is the most common ligand 
for zinc (27, 28) raised the possibility that H81 could be ac- 
tively involved in a zinc coordination with SEA. Zinc ac- 
tively participates in other ligand-receptor and protein-pro- 
tein interactions  (29-33). 
In this study, we have examined the nature of SEA binding 
to HLA-DR1 and have identified two separate nonoverlap- 
ping MHC class II binding sites on SEA. One binding site 
is low affinity and appears to be identical to SEB, involving 
F47 in the NH2-terminal  domain. The second high affinity 
site involves a tetravalent zinc bridge between SEA and the 
H81 in the B chain of MHC class II on the opposite  side 
of the molecule. Thus, in addition to activating T cells by 
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presses MHC  class II,  including  the APC. 
Materials  and  Methods 
Plasmids and Proteins.  Recombinant SEA, SEB, SED, and SEE 
were produced in Escherichia coli using the expression vector pGeX. 
The construction of plasmids pGeX-SEA and pGeX-SEE have been 
described previously (18). The plasmids pGeX-SEB and pGeX-SED 
were constructed for this study. The SEB and SED genes were 
generous gifts from Dr. S. A. Khan (Department of  Microbiology, 
University of Pittsburgh School of Medicine, Pittsburgh, PA) and 
Dr. J. J. Iandolo (Microbiology Group, Division of  Biology, Kansas 
State  University, Manhattan,  KS),  respectively. 
Plasmids encoding site directed mutants of SEA were constructed 
by PCR overlap and cloned into the pGeX plasmid  (34, 35). All 
gene constructions were verified by DNA sequencing. The plasmid 
pGeX-SEB produces rSEB that has the wild-type NHz-terminal 
glutamic acid replaced by a glycine residue, whereas the rSED pro- 
duced has an additional glycine residue on the NH2 terminus. 
All recombinant proteins were purified by affinity chromatog- 
raphy on glutathione-agarose as described previously (18). Toxins 
were released from the fusion protein by cleavage with N-l-tosyla- 
mide-2-phenylethylcholoromethyl ketone-treated trypsin (Sigma 
Immunochemicals, St. Louis, MO), apart from SEB that was released 
by bovine thrombin (Dade International, Deerfield, IL). All recom- 
binant proteins gave a single band on SDS-PAGE of the expected 
molecular weight. Soluble HLA-DR1 was released from the B-lym- 
phoblastoid cell line LG-2 by papain  cleavage and purified as de- 
scribed previously (36). 
Peptides.  Peptides were obtained from Chiton Mimotopes (Vic- 
toria, Australia)  and were >95%  purity by HPLC. The peptide 
corresponding to the region 71-85 of the fl chain of HLA-DR1 
had the sequence RRAAVDTYCRFINYGV. The two variants of 
this peptide were identical except that H81 (underlined) was sub- 
stituted by glutamic acid or tyrosine. An irrelevant  peptide con- 
taining histidine HIVFHTSTEPSVNYDLFG was synthesized by 
Immunex Corp. (Seattle, WA). The two jumbled versions of fl71- 
85 were J1-RRAAVDTYRYHNVGC and J2-TVAYVGRYCAHN- 
RDR. All peptides were treated at 1 mM with 2 mM iodoaceta- 
mide for I h before use to reduce zinc binding to the free cysteine 
residue. 
Human PBL Stimulations.  Human peripheral blood lymphocytes 
from healthy volunteers were purified on Ficoll (Histopaque-1077; 
Sigma)  as recommended by the manufacturer and washed twice 
with RPMI 10% FCS. Recombinant toxin proteins were titrated 
over eight orders of magnitude by fivefold serial dilution and tested 
in triplicate by standard [3H]thymidine incorporation assays with 
2.5  x  10  s PBL per well. 
Determination of Relative Binding Affinities of SEA  to  LG-2 
Cells.  The binding affinity of mutant SEA proteins to MHC class 
II was determined as described previously (37). Comparative affinity 
was determined by a competitive binding assay of a fixed concen- 
tration  of 12SI-labeled SEA  binding  to  LG-2 cells  (HLA-DR1 
homozygous) at 37~  Standard errors in these experiments were 
<  _+ 15%. The amount of each variant required to inhibit binding 
of nsI-SEA by 50% was normalized against the amount of SEA 
required to cause  the same level of inhibition. 
Competition of  SEB Binding to LG-2 Cells.  I mg of recombinant 
SEB was incubated at room temperature for 2 h in 1 ml of 0.1 M 
borate, pH 8.5, containing I mg FITC then separated on an NAP10 
column (Pharmacia Fine Chemicals,  Piscataway, NJ). For competi- 
tion assays, 5  x  104 LG-2 cells were incubated for 2 h at 37~ 
in 20 #1 PBS/10% FCS containing 1.5 or 3.0 #M FITC SEB and 
0.15-15  #M of uulabded toxins, Cells  were washed twice with 
ice-cold  PBS/10%  FCS  and  then  analyzed  immediately  on  a 
FACScan  |  (Becton & Dickinson Co., Mountain View,  CA). 
V~ Enrichment Analysis by Anchored Muhiprimer Amplification. 
TCR VB gene enrichment in human PBL cultures was determined 
as previously described (18). In brief, freshly isolated PBL were cul- 
turecl at 106 cells per ml for 3 d in the presence of 10 ng/ml recom- 
binant toxin. Human IL-2 was added on day 3 and cells were har- 
vested on day 4. RNA was extracted (38) and reverse transcribed 
using a TCR O chain-specific primer. A total VO probe was gener- 
ated by PCR using two redundant primers containing inosine. Rel- 
ative expression of individual TCR VB cDNA species was deter- 
mined by reverse dot blot hybridization of the total VO probe to 
filters containing 15 different human VO DNA segments. 
6SZinc Binding Assays.  Toxins were incubated at 0.42 mg/ml 
(15 #M) in a final volume of 12 ~1 with 18 #M EDTA, followed 
by addition  of 6sZnClz 0.2  mCi/mg;  New  England  Nuclear, 
Boston, MA) to 36 #M for 2 h at 37~  The buffer used was 150 
mM NaC1,  10 mM MgClz 20 raM Tris, pH 7.3, that had been 
treated with chelex resin (Sigma) to remove free zinc. A Hybond 
C membrane (Amersham Corp., Arlington Heights, IL) was treated 
with 1 mM EDTA and rinsed in zinc-free buffer.  Treated toxins 
were blotted in triplicate to the membrane for 20 min using a 96- 
well filtration manifold (Life Technologies,  Gaithersburg, MD). 
Each well was rinsed under vacuum with 5 x  200 #1 zinc free buffer. 
The membrane was removed and washed twice for 2 min in the 
zinc-free buffer. The membrane was autoradiographed, then each 
dot was cut out and counted for bound 6SZn. Control membranes 
were stained  for protein with Coomassie blue R  and washed in 
45% methanol, 7% acetic  acid. 
For some experiments, purified HLA-DR1 was added to 15 #M 
with the toxins, and all following steps were the same as above. 
The degree of zinc entrapment was determined by replacing the 
two final 2-min washes in zinc-free buffer with two 2-min washes 
in 10 #M EDTA. 
For zinc-trapping experiments involving peptides,  toxins were 
incubated at 0.42 mg/ml (15 #M) with 20-fold molar excess of 
the peptide in a final volume of 18 #1 with 18 #M EDTA, followed 
by addition of 6SZnClz (3.2 mCi/mg; New England Nuclear) to 
36 #M for 2 h at 37~  The zinc-free buffer consisted of 150 mM 
NaC1,  10 mM MgCIz,  40 mM  Hepes,  pH  7.3.  Samples  were 
blotted in triplicate to the Hybond C membrane as described above, 
and the blots were washed under vacuum with 3  x  200 #1 of the 
zinc-free buffer. For SEA-H225A, blots were removed washed twice 
with zinc free buffer before autoradiography. For SEA-H187A, blots 
were washed once for 2 rain with 10 #M EDTA and then once 
with zinc-free buffer. Counts were quantified by punching out the 
dots and counting them for 6SZn. Data does not reflect equilib- 
rium conditions so stoichiometries of zinc binding cannot be de- 
termined. 
Results 
Mapping  of the High Affinity Zinc Site  in SEA.  During 
PCR amplification of the SEA gene, a clone was identified 
with a random point mutation that changed residue H187 
to R187 (henceforth written H187R). This mutant SEA gene 
and a second deliberately constructed SEA-H187A mutant 
were expressed in E. coli, and the purified recombinant pro- 
rein was assayed on PBLs and compared to wild-type SEA. 
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quently found to be caused by reduced MHC dass II binding. 
Because SEA binding to MHC class II has an essential re- 
quirement for a zinc atom (23), we speculated that H187 might 
be a part of a zinc binding site. Histidine is the most common 
of zinc binding amino acids (28). The mutants SEA-H187R 
and a similar SEA-H187A mutant were tested for direct 6SZn 
binding using a simple dot blot assay to comparatively mea- 
sure relative 6SZn binding, and the results for the latter mu- 
tant are shown in Fig.  1.  SEA-H187A bound significantly 
lower levels of 6SZn than wild-type SEA. After this finding, 
all other histidine, asparatic acid, and glutamic acids in the 
final 46 COOH-terminal region of SEA were individually 
mutated to alanine.  There are four such positions at E191, 
E222, H225, and D227.  The COOH-terminal domain was 
thought to contain all the zinc ligands because it had previ- 
ously been shown that a 107-233 COOH-terminal fragment 
of SEA still bound to MHC class II (39).  Furthermore, a 
common zinc binding motif L1-X~_3-L2-X2o-4o-L3  found in 
most zinc metalloproteins (other than zinc finger proteins) 
(27, 28, 40) could be applied to this region if the L1 position 
was assumed to be H187.  Each purified mutant was exam- 
ined in the direct 6SZn binding assay, and the results of this 
analysis are shown in Fig.  1 a.  In comparision to SEA, the 
mutants SEA-H187A, SEA-H225A, and SEA-D227A all had 
6SZn binding that was 10->35-fold less, while SEA-E191A 
and  SEA-E222A  actually displayed  a  2-3-fold  increase in 
6SZn binding.  Thus zinc was dependent on H187,  H225, 
and D227, but not E191 and E222, even though these latter 
residues were in close proximity to H187.  The zinc motif 
for SEA appears  to be a mirror image of the common zinc 
motif.  In this case,  it  is L1-X38-X-L3. 
Loss of zinc binding correhted directly  with decreased HLA- 
DR1 binding affinity and reduced proliferation activity on 
human PBL (Table 1). Notably, H225A and D227A muta- 
tions abolished the ability of SEA to compete for wild-type 
t2sI-SEA binding to LG-2 cells, whereas the H187A muta- 
tion had a more moderate effect on both MHC class II binding 
and proliferation (Table  1). This was attributed to the fact 
that residue H187 was not as important to zinc binding as 
H225 or D227 are. Fig.  la shows that the SEA-H187A mu- 
tant  bound  more 6SZn than  SEA-H225A  under the same 
conditions. Although the total 6SZn counts for SEA-H187A 
were only slightly more than SEA-H225A after washing of 
the filters, small differences in 6SZn  bound at nonequilibrium 
conditions reflect a significant difference in the dissociation 
rates of 6sZn. This is because the monophasic dissociation 
of 6SZn from its single site follows an asymptotic curve. Fur- 
ther studies have shown that SEA-H187A binding to MHC 
class II can be increased to wild-type levels if the solvent zinc 
concentration is raised above 10/zM.  This concentration is 
only 10-fold  higher than that which is required to sustain 
50% of maximal binding for wild-type SEA (0.7/zM) (23). 
In contrast, SEA-H225A and SEA-D227A binding to MHC 
class II is not significantly improved by zinc levels >100/zM 
(data not  shown). 
Other  staphylococcal enterotoxins  were also  tested  for 
6SZn binding  in  the  dot  blot  assay. Both  SEE  and  SED 
bound 6SZn, but SEB did not (Fig.  1 a). This indicated that 
Figure 1.  Mapping the zinc coordinating residues of SEA. (a) Toxins 
were incubated with 6sZn, dot blotted to nitrocellulose, washed, and au- 
toradiographed. The individual dots were counted for ~Zn. Parallel blots 
were stained for protein.  Because of the washing steps, this assay shows 
comparative binding of 6SZn only. The dpm values represent only a pro- 
portion of the 6sZn that would normally be bound to each toxin under 
equilibrium  conditions. (b) Residues in the aligned sequences of the wild- 
type toxins present at the equivalent position of the zinc-binding  residues 
of SEA. The single letter amino acid code is used. 
Table  1.  HLA-DR1  Affinity  and Potencies of SEA 
and SEA  Mutants 
Mutant  Relative binding  affinity  Ps0 (pg/ml) 
SEA  1  2 
SEA-H187A  40  66 
SEA-E191A  1  1.0 
SEA-E222A  1  0.8 
SEA-H225A  1,000  1,000 
SEA-D227A  10,000  )10,000 
SEA-F47S  6  130 
SEA-F47S.H187A  10,000  10,000 
The relative binding  affinities of SEA mutants were determined by com- 
paring inhibition of 12si SEA binding to LG2 cells (DR1 homozygous) 
with inhibition  by wild-type SEA. Stimulation potency was determined 
on human peripheral blood lymphocytes. The figures represent the con- 
centration giving 50% of the maximum 13H]thymidine incorporation. 
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SEB based on their ability to bind zinc. This segregation into 
the two families is consistent with the conservation of amino 
acid sequence. While SEA, SEE, and SED share >70% amino 
acid homology, SEB is only 30% homologous to the former 
toxins. Fig. I b shows the amino acids at the equivalent SEA 
positions of 187,  225,  and 227 in the aligned sequences of 
these toxins (9). The conserved pattern of these residues in 
SEA, SEE,  and SED but not SEB supports the conclusion 
that the identified residues are involved in zinc coordination. 
Toxic shock syndrome toxin, which also does not require zinc 
for MHC class II binding, likewise does not have these residues 
conserved (Fig.  1 b; reference 9).  Crystallographic  analysis 
of zinc binding proteins shows that zinc is typically coordi- 
nated by four ligands.  In all cases where the zinc ion is sol- 
vent exposed and involved in either catalytic or cocatalytic 
processes, the fourth ligand is a water molecule (27, 28, 30). 
A molecular model of SEA built from the SEB crystal struc- 
ture (Homology and Discover computer programs; Biosym 
Technologies,  San Diego,  CA),  reveals  that  the zinc atom 
is located on the surface of SEA and furthermore is not adja- 
cent to any other potential zinc ligands (i.e., His, Asp, Glu, 
or Cys side chains) other than H187, H225, and D227. Thus 
the fourth  zinc ligand  in free SEA is most likely a water 
molecule. 
Mutation in the High Affinity Binding Site Does Not Alter 
TCR VB Specificity.  The physical separation of the zinc site 
from the TCR binding site was examined functionally using 
SEA-H187A to stimulate human PBLs at a limiting concen- 
tration.  The V~ enrichment profile of SEA-H187A was es- 
sentially identical to that  of wild-type SEA, except that  T 
cells bearing V~1.1  and V~9 were not enriched  (Table 2). 
These particular V~s have previously been found to be more 
sensitive to SEA concentration  than the others and are the 
first to disappear as the SEA concentration becomes limiting 
(18) suggesting that the lack of enrichment  of hV~l.1  and 
hvBg.1  in  response  to  SEA-H187A  resulted  from weaker 
binding to MHC class II, not from an altered TCR binding 
site. In addition, no new VBs were enriched by SEA-H187A, 
indicating that mutations that alter zinc binding do not affect 
the TCR binding  site. 
Zinc Is Sandwiched between SEA and DR1.  To determine 
whether the zinc atom was actively involved in the SEA-MHC 
class II interaction, SEA, SEA-H187A, and SEA-H225A were 
incubated with purified HLA-DR1 in the presence of 6SZn. 
SEA-H187A  and  SEA-H225A  showed  little  if  any  6SZn 
binding alone, but the combination of these mutants with 
an equimolar  amount  of DR1  reconstituted  6SZn binding 
(Fig.  2 a). 
For wild-type SEA, however, the presence of purified DR1 
did not significantly increase the level of 6SZn binding over 
that seen for SEA alone. Presumably, the wild-type SEA was 
already saturated with  zinc under  these conditions. 
Evidence that zinc is sandwiched in a hydrophobic inter- 
face between SEA and MHC class II is provided in Fig.  2 
b. These results show that 6SZn was not removed from the 
SEA/DR1 complex by EDTA washing under conditions that 
Table  2.  Mutation in MHC Class II Binding Site Does Not 
Affect  TCR  V~ Specificity 
VB/C~ (%) 
TCR (VB)  Unstimulated  PBL  SEA  SEA-H187A 
1.1  1.8  _+  0.05  4.3  •  0.01  1.4  •  0.2 
2.1  5.8  +  0.1  <1  1.1  •  0.01 
3.2  5.4  •  0.2  1.3  _+ 0.05  3.6  •  0.2 
4.1  8.8  •  0.1  <~1  1.5  •  0.01 
5.1  4.8  •  0.1  4.2  •  0.1  3.4  •  0.1 
5.3  5.3  +  0.3  15  •  1.3  8.5  •  0.1 
6.3  1.4  •  0.2  9.6  •  0.01  9.6  +  0.1 
6.4  1.8  •  0.01  9.4  +  0.05  9.8  •  0.1 
6.9  5.0  _+  1.0  24  •  1.0  22  •  0.5 
7.4  5.8  _+ 0.4  17  •  1.7  14  +  0.5 
8.1  9.4  _+ 0.3  3.2  •  0.5  4.6  •  1.1 
9.1  1.0  _+ 0.1  4.0  •  0.3  1.6  _+  1.1 
12.5  9.6  +_ 0.5  2.7  •  0.2  6.6  •  0.1 
15.1  1.6  _+ 0.1  <1  1.4  •  0.07 
23.1  <1  2.6  •  0.5  3.4  •  0.2 
Total (%)  68  98.6  91.6 
Human PBL were stimuhted with 10 ng/ml of SEA or SEA-H187A for 
4 d and the TCR V/3 stimulation profile was determined (18). Data reflects 
the ratio of individual V/3s with respect to total C~. Each assay was per- 
formed in duplicate.  Those VBs in boldface were enriched with respect 
to unstimulated  hvels. 
effectively stripped 6SZn from free SEA.  This resistance to 
EDTA was also seen with both SEA-H187A/DR1 and SEA- 
H225A/DR1 comple~s, reflecting the strong stab'tlizing effect 
of MHC class II on zinc coordination. These results support 
a model where zinc bridges between SEA and MHC class 
II and is buried in a fourfold coordination complex within 
the interface of the two molecules. 
Zinc Is Coordinated by 1-181 of the HLA-DR ~  Chain in the 
SEA-DR Complex.  Mutational studies of MHC class II have 
shown that the conserved H81 in the B chain of MHC class 
II is the only residue which significantly reduces SEA but 
not SEB binding (10, 26, 41). To test whether H81 in DRB 
represents  the fourth zinc ligand,  a peptide corresponding 
to region 71-85 of HLA-DR1/3 chain was synthesized and 
tested as a replacement for purified DR1 in the zinc trapping 
experiment. At 20-fold molar excess, DRB71-85 partially re- 
stored high af~nity 65Zn binding to both SEA H187A (Fig. 
3 a) and SEA-H225A mutants (Fig. 3 b). As a control, five 
other peptides were synthesized and tested in the same assay. 
Two of these control peptides were identical to the DR71-85 
peptide, e~ept that position 81 was substituted by either tyro- 
sine or glutamic acid. Neither of these peptides restored zinc 
binding nor did an irrelevant  histidine-containing  peptide. 
714  Staphylococcal Enterotoxin A  Has Two Binding  Sites on MHC Class II Figure  2.  Zinc directly bridges binding of SEA to HLA-DK1. (a) Toxins 
were incubated  with an equimolar quantity of purified  HLA-DK1 and 
6SZn, dot blotted to nitrocellulose,  autoradiographed,  and the individual 
dots were counted for 6sZn. Parallel blots were stained  for protein.  (b) 
Toxins were incubated  with 6sZn and an equimolar quantity of purified 
HLA-DR1, dot blotted to nitrocellulose,  and washed with 10 #M EDTA 
before  autoradiography  and counting. 
Although glutamic acid is potentially able to coordinate zinc, 
replacement of histidine for glutamic acid in the DR 71-85 
peptide did not reconstitute 6SZn binding to either SEA- 
H187A or SEA-H225A.  Charge or steric characteristics of 
glutamic acid may be responsible for this  difference. 
In addition to the contribution of H81  to zinc binding, 
the involvement of other adjacent residues in the DR71-85 
peptide not directly associated with zinc binding were ana- 
lyzed.  Two scrambled versions of DR1~71-85  were tested. 
The first of these, J1, reconstituted zinc binding to both mu- 
tants as well as the native 71-85 peptide. The second scram- 
bled peptide, J2, was ineffective. The J1 peptide differed from 
the original only in residue on the opposing face of the c~ 
helix away from H81 (42). That is, positions C79, R80, Y83, 
and V85 were scrambled. The J2 peptide on the other hand 
was more extensively jumbled and had changes at positions 
R71, R72, A74, D76, T77, R80, Y83, G84, and V85. These 
mutations altered residues extending out in the same direc- 
tion as H81 in the DR1 ~ chain and would therefore be more 
likely to make contact with SEA. Thus, in addition to H81, 
residues in close proximity and pointing out in the same direc- 
tion as H81 influenced specific coordination of zinc, at least 
Figure 3.  Identification of the HLA-DR1 residue involved in the tetrava- 
lent coordination of zinc with SEA. (a) SEA-H187A was incubated with 
20-fold molar excess  ofpeptides corresponding to either DR1/?71-85, variants 
at position 81, an irrelevant histidine containing peptide,  or two jumbled 
versions of DR71-85-J1 and J2. Incubations  were performed in the pres- 
ence of 6sZn, dot blotted to nitrocellulose,  washed briefly with 10/~M 
EDTA, autoradiographed,  and the individual dots were counted  for 6sZn. 
(b) SEA-H225A  was incubated  with 20-fold molar excess of peptides  in 
the presence of 6sZn and treated in a similar fashion, except that the final 
blot was not incubated with EDTA. The final two rows were the DR71- 
85 and J1 peptides  in the absence of any toxin. 
in this assay. SEB plus the DR1/371-85 peptide did not bind 
significant levels of 6SZn over and above the amount of 65Zn 
that was bound by the peptides alone (Fig. 3 a). These data 
imply that DRBH81 represents the fourth zinc ligand in SEA- 
DR1 complex and would explain why mutations in DRBH81 
only affect SEA and SEE binding but not SEB binding. 
Location of  a Second  MHC Class II Binding Site on SEA.  Fur- 
ther mutational analysis located a second contact point with 
MHC class II in a region of SEA quite distant from the zinc 
atom. While SEA and SEB appear to bind in quite different 
ways to MHC dass II, SEA still strongly inhibits SEB binding 
(2). Residue F44 in the NH2-terminal domain of SEB is cen- 
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lent SEA residue (F47)  was mutated to determine whether 
SEA also used this region to bind to MHC class II. A single 
mutant, SEA-F47S, and a double mutant, SEA-F47S.H187A, 
were generated and expressed in E. coli and tested for MHC 
class II binding and rdative T cell potency using the standard 
human PBL stimulation assay. The single mutant SEA-F47S 
displayed a 6-fold reduction in MHC class II binding and 
a 250-fold reduction in T  cell proliferative response (Table 
1). In contrast, SEA-H187A exhibited a 40-fold drop in bind- 
ing to MHC class II but retained similar T ceU proliferative 
activity as SEA-F47S. The double mutant SEA-F47S.H187A 
had undetectable binding and a 10,000-fold loss in activity. 
Thus a mutation in the NH2-terminal region of SEA (F47S) 
affected T cell proliferation more than it affected MHC class 
II binding compared to a mutation on the other side of SEA 
at the zinc site (H187A). These data suggested that binding 
of SEA via F47S might be less important on total binding 
affinity and more important for direct TCK ligation, while 
the zinc site might be important for initial binding to MHC 
class II in an orientation not directly associated  with TCK 
ligation. To reconcile these results, a model of two SEA mol- 
ecules bound to one MHC class II molecule was invoked and 
tested. 
SEA and SEB Share the Low Affinity but Not the High A~nit? 
Binding  Site.  Mutants  in  the COOH-terminal  and NH2- 
terminal binding site were tested for their ability to inhibit 
SEB binding to DK1 expressing LG-2 cells (Fig.  4 a). SEB 
has been shown to bind exclusively to the DR1 o~ chain (11). 
Fluoresceinated SEB was incubated at 3.0 #M and unlabded 
toxins were added at  15 #M (fivefold excess).  Specific SEB 
binding to LG-2 cells was inhibited by unlabeled SEA, SEB, 
and SEA-H225A.  Surprisingly, SEA-H225A was the best com- 
petitor of all, reducing specific SEB binding by nearly 90%, 
even though this mutant had lost any high affinity zinc/DK/3 
chain binding. Thus, the remaining low affinity binding site 
in the NH2-terminal domain of SEA-H225A was still suffi- 
cient to compete for SEB binding. This provided convincing 
evidence that SEA and SEB bound to the DKcx chain in an 
identical  fashion  via  the  NH2-terminal  globular  domain. 
The double mutant SEA-F47S.H187A, as expected, did not 
inhibit SEB binding at all because both sites had been mutated. 
Instead of having no effect, SEA-F47S significantly increased 
SEB binding over that seen in the absence of any competitor. 
This suggested a cooperative effect between an SEA-F47S mol- 
ecule bound exclusively to the 13 chain binding site and an 
SEB molecule occupying the ot chain binding site. Significantly, 
cooperative binding occurred between two different super- 
antigens, i.e., SEA and SEB. This cooperative effect was ana- 
lyzed in more detail (Fig. 4 b). FITC-SEB was bound to LG-2 
cells at  a lower concentration than in the previous experi- 
ment in the presence of 0.1-10-fold excess of either SEA-F47S 
or SEA-H225A. As before, SEA-H225A effectively  inhibited 
SEB binding at aU concentrations tested while SEA-F47S pro- 
gressively increased SEB binding. This increase was maximal 
at  the molar equivalence point of SEA-F47S  and SEB. 
The reverse experiment was performed to show that cooper- 
ativity existed in both directions. Radiolabded SEA-F47S was 
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Figure 4.  Competition for SEB binding by SEA mutants.  (a) Fluores- 
ceinated SEB was incubated  at 3.0/~M with LG-2 cells in the presences 
of 15 #M (fivefold  e~cess) SEA, SEA-F47S,  SEA-H225A, SEA-F47S.H187A, 
or unlabeled SEB. Cells were incubated  at 37~  for 2 h before washing 
and FACS  |  analysis. MFI, mean fluorescence intensity.  Each value is the 
average of duplicate samples. (b) Cells were incubated with 1.5 #M FITC 
SEB in the presence of 0.15-15 #M SEA-H225A (,), 0.15-15 #M SEA- 
F47S (O), or no competitor (Q). 
incubated with LG-2 cells in the presence of each toxin mu- 
tant  and  the  results  are  shown  in  Fig.  5.  12sI-SEA-F47S 
binding to the DR1 13 chain was inhibited by both SEA and 
SEA-F47S, but binding was increased by both SEA-H225A 
and SEB. Maximal cooperativity occurred at a molar ratio 
of 1:1,000, which reflected the large difference in affinity be- 
tween the t3 chain binding site and the ol chain binding site. 
Thus, cooperative binding was again observed beween two 
SEA molecules, as well as SEA-F47S  and SEB. 
Discussion 
Two Cooperative Binding Sites on SEA for MHC  Class II. 
Unlike SEB, SEA has a second binding site to the polymorphic 
13 chain of MHC class II mediated by a tetravalent zinc coor- 
dination complex between H187,  H225,  and D227 in SEA 
and H81  in the DR1 13 chain oL helix. The zinc site is on 
the opposite side of the SEA molecule to the F47.L48 motif 
conserved between SEA, SEB, and other superantigens,  which 
allows them to bind to the invariant MHC class II o~ chain 
(11). Zinc-mediated  binding is unique to SEA, SEE, and SED 
(Fig.  1),  and given the degree of similarity between these 
three toxins, it is likely that that SEE and SED also bind to 
MHC class II in  two  separate orientations. 
Has Two Binding  Sites on MHC Class II 15o 
lOO- 
5o 
u) 
.< 
o 
1  lO  lOO  looo  1000o 
ratio of [competltor/SEA-F47S] 
Figure  5.  Competition for SEA-F47S binding to HLAoDK1. Radiola- 
beled SEA-F47S (50 #Ci/#g) was incubated  with purified  DR1 in the 
presence of increasing amounts of either SEB (O), SEA-H225A (￿9  SEA 
(0),  or SEA-F47S ([3) at 37~  Each point is the average of duplicate 
samples. The percentage  error was <5%. 
Binding of two toxin molecules to the same DR1 mole- 
cule displayed distinct cooperativity. This was demonstrated 
by the ability  of SEA-F47S to  significantly  enhance SEB 
binding while SEA-H225A strongly inhibited, even though 
zinc-mediated binding had been destroyed (Fig. 4). This was 
dear evidence that SEA-H225A had retained its DR c~ chain 
site while SEA-F47S had retained its DR/3 chain binding 
site. Because the atfinity of  SEA to the/3 chain is much greater 
than to the ot chain, this would ensure that SEA first binds 
to the DR/3 chain and then assists the binding of a second 
molecule to the DR ot chain site. The cooperative effect most 
likely occurs via direct contact between the two SEA mole- 
cules bound to either side of the DR ot helices although this 
has yet to be formally proven.  Dependence on initial  DR 
/3 chain binding would explain why mutations that alter zinc- 
mediated  binding (24, 26) have such a dramatic effect on SEA 
activity despite the fact that the DR c~ chain site remains intact. 
These data resolve previous confusion about SEA and SEB 
binding to MHC class II. For example, while SEA prevents 
SEB binding, SEB does not inhibit SEA binding, even at 
10,000-fold molar excess  (21, 22). Because  SEA and SEB com- 
pete only for the low affinity DR c~ chain site, zinc-mediated 
DR B chain binding is unaffected by SEB. 
The Nature of the Zinc Site in SEA.  The relative contri- 
bution of individual SEA residues to zinc binding varied in 
the order D227 ~> H225 ~> H187. The importance of D227 
suggests that this residue may act as a bidentate ligand,  as 
seen in other zinc binding proteins  (43). The bridging of 
SEA to MHC class II via zinc most likely involves a rear- 
rangement of the zinc coordination complex between free 
and bound states of  SEA. We hypothesize that a water mole- 
cule bound to zinc in free SEA is replaced by H81  in the 
/3 chain of HLA-DR1. However, the potential  of D227  to 
act as a bidentate ligand could reflect a more complex rear- 
rangement. Notably, high affinity binding of SEA to MHC 
class II is strongly temperature dependent (2, 22), suggesting 
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that the change in coordination state of the zinc atom is en- 
dothermic and may involve a structural change in one or more 
residues in or close to the binding site. For example, H81, 
which is normally hydrogen  bonded to the peptide backbone 
in dass II (42), may need to shift to interact with the zinc atom. 
While the zinc atom is essential to binding, other regions 
of SEA have  been identified, notable the very NH2-terminal 
residues that also modulate high atfinity binding (references 
19, 44, and Hudson, K., unpublished  data). In a model of 
SEA bound to DR1/3  chain (see Figs. 6 and 7), the very 
NH2 terminus of SEA would be in close proximity to DR 
and may also participate in the interaction.  Although MHC 
class II/3 chains are highly polymorphic, these differences 
do not significantly alter SEA binding and/or presentation, 
even between species apart  from the DRw53 allele, which 
has a H81Y change (24, 26). The recruitment of  a metal atom 
may represent a means by which toxin binding can be sus- 
tained to a highly polymorphic protein domain with min- 
imal dependence on surrounding residues. 
Possible SEA/MHC Class II Structures and Ligation of TCR. 
In the absence'of an SEA crystal structure, a model is provided 
in Fig. 6, based on the SEB crystal structure (11), that shows 
the location of the two MHC class II binding regions and 
the region that interacts with TCR (18, 19, 37). The analo- 
gous residues in SEB to the zinc site are I190 (H187) on the 
exposed loop between the two/~ strands/~9 and/310, whereas 
K229 (H225) and E231 (D227) are on the closely associated 
/~12 strand. The similarity between SEA and SEB in this re- 
gion is sufficiently high to allow the reconstitution of a zinc 
site in SEB (Tiedemann,  R.,  manuscript in preparation). 
The three-dimensional structure of an SEB/DR1 cocrystal 
reveals that SEB contacts the DR ol chain through residues 
F44 and L45 (analogous to F47 and L48 in SEA) (11). Residues 
I190, K229, and E231 in SEB, which represent the zinc site, 
point out and away from the DR1 structure and clearly do 
not interact  with any portion of the same DR1 molecule. 
This region of the SEA molecule could interact with another 
Figure 6.  Relative position of the two MHC class II binding sites on 
SEA. The zinc atom chelated by H187,  H225, and D227 in SEA. The 
position of these residues is based on the location of analogous  residues 
(I190, 1(229, and E231) in the crystal structure of SEB (17). H187 is lo- 
cated on the inner descending strand of the 159-B10 loop, while H225 and 
D227 are located on the ascending B-12 strand.  Residues E191 and E222 
are also indicated,  even though mutation of these adjacent residues had 
no negative effect on zinc binding or activity. The position of F47 in the 
NH2-terminal  domain of SEA is shown along with $206, N207, which 
are TCR contact residues. Figure  7.  A hypothetical  model of SEA binding to MHC class II. This figure is drawn  (Insight  II; Biosym) from the coordinates of the SEB/DR1 
crystal structure  (11). SEA is light gray and the DR.~x helices and peptide  are dark  gray. Residues in the two binding sites on opposite  sides of the 
SEA molecule are drawn in baU-and-stick form.  The low a~nity interaction  via F47 (labeled) to the DRc~ chain is shown bound in the same manner 
as SEB, while the zinc site is shown contacting H81  (labeled) on the DP,  B chain.  Two possible complexes are shown:  one where SEA binds  two 
DR1  molecules and  a second where one DR1 molecule  binds  two SEAs. Extensive MHC class II cross-linking  would result. 
DR B chain via H81 and a hypothetical structure is shown 
in  Fig.  7. 
These data predict that  one MHC class  II molecule can 
bind two SEA molecules simultaneously or alternatively,  one 
SEA molecule can cross-link two MHC class II molecules. 
Under normal in vivo conditions,  MHC class  II would be 
in considerable excess  to SEA  so the SEA.DK12 structure 
would be most favored. Because of the significant coopera- 
tivity evident between the two sites, however, an SEAzDR1 
trimer may still be favored, even at low SEA concentrations. 
Recent experiments  with soluble DR1 and SEA have con- 
firmed  the  existence  of SEAzDK1  complexes  in  solution 
(Tiedemann,  K.,  manuscript  submitted  for publication). 
Why Does SEA  Have Two Binding Sites on MHC Class 
II?  SEA requires two binding sites to activate T ceils, whereas 
SEB needs only one. One obvious purpose of the second B 
chain binding site on SEA might be to recruit and stabilize 
the primary c~ chain binding at concentrations far below the 
dissociation  constant of the c~ chain binding alone. This would 
allow SEA to be active at much lower concentrations.  Two 
binding  sites may also allow SEA to cross-link MHC class 
II molecules, ddivering activation signals to both the APC 
and the T  cell (40). This may upregulate surface expression 
of costimulatory molecules such as B7 (46) and induce cytokine 
secretion by the APC, which helps T cell activation. Recent 
evidence suggests that for optimal activity, both binding sites 
must be on the same SEA molecule (Tiedemann, K., unpub- 
lished data),  suggesting that  MHC class II cross-linking is 
one aspect of SEA function essential for maximal T cell acti- 
vation. 
It is unusual that SEB-like binding and activation have not 
been fully conserved by SEA despite retention of the DKcx 
chain binding. This mechanistic difference may lie in the na- 
ture of the TCR binding site. SEA activates a broader range 
of TCR Vfls than SEB. In humans, SEB predominantly targets 
Vfl3-bearing cells while SEA targets h Vfll.1, 5.3, 6.3, 6.4, 
6.9,  7.3, 7.4, 9.1,  and 23.1 (18).  The cost of this larger Vfl 
repertoire may be a reduced affinity for individual TCRs so 
that binding to a single site on the class II o~ chain is no longer 
sufficient to activate most T cells. Costimulatory signals may 
be essential to enhance the lower affinity SEA/TCR interac- 
tion,  and this may have been achieved by additional  cross- 
linking MHC class II. The fact that an SEA-H225A/MHC 
class II complex is insufficient for T  cell activation suggests 
that the affinity of SEA towards TCR is too low to deliver 
an activation signal on its own without additional costimu- 
lation. 
Despite the fact that  polymorphisms  in  either  TCR or 
MHC class II do not significantly alter SEA activity, MHC 
class II is still important for activation by SEA. This has always 
718  Staphylococcal Enterotoxin A  Has Two Binding  Sites on MHC Class II been used as a strong argument favoring essential TCR. MHC 
class II interactions in superantigen activation and may be 
so for SEB. However, the more important role of MHC class 
II in SEA activation may be to mediate the recruitment of 
costimulatory molecules to the surface of the APC. This may 
in turn reduce the need for strict compatibility between the 
TCR and MHC class II peptides, again allowing SEA to ac- 
tivate many more T  cells at much lower concentrations. 
The data presented here indicate that the superantigen SEA 
has developed a novel mechanism to bind to the highly poly- 
morphic MHC class IIB chain. The net effect of this is to 
enhance binding of a second SEA molecule to the crucial class 
II ol chain site and to cross-link MHC class II on the surface 
of the APC,  thus activating costimulatory pathways and 
coalescing MHC class II on the APC surface, further enhancing 
its ability to activate T  ceils. This increased  potency must 
provide an important advantage for Staphylococcus aureus strains, 
which produce these superantigens. 
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